Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 567387, 6 pages
http://dx.doi.org/10.1155/2015/567387
Research Article

Association between Ophthalmic Timolol and Hospitalisation for Bradycardia

Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia

Received 3 June 2014; Revised 20 August 2014; Accepted 18 September 2014

Academic Editor: Suddhasil Mookherjee

Copyright © 2015 Nicole L. Pratt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Resnikoff, D. Pascolini, D. Etya'ale et al., “Global data on visual impairment in the year 2002,” Bulletin of the World Health Organization, vol. 82, no. 11, pp. 844–851, 2004. View at Google Scholar · View at Scopus
  2. G. D. Novack, M. J. O'Donnell, and D. W. Molloy, “New glaucoma medications in the geriatric population: efficacy and safety,” Journal of the American Geriatrics Society, vol. 50, no. 5, pp. 956–962, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Dirani, J. G. Crowston, P. S. Taylor et al., “Economic impact of primary open-angle glaucoma in Australia,” Clinical & Experimental Ophthalmology, vol. 39, no. 7, pp. 623–632, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. J. Walland, “Glaucoma treatment in Australia: changing patterns of therapy 1994–2003,” Clinical and Experimental Ophthalmology, vol. 32, no. 6, pp. 590–596, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. F. Kirwan, J. A. Nightingale, C. Bunce, and R. Wormald, “Do selective topical β antagonists for glaucoma have respiratory side effects?” British Journal of Ophthalmology, vol. 88, no. 2, pp. 196–198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. W. C. Stewart and P. M. Garrison, “β-Blocker-induced complications and the patient with glaucoma: newer treatments to help reduce systemic adverse events,” Archives of Internal Medicine, vol. 158, no. 3, pp. 221–226, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Diggory, P. Heyworth, G. Chau, S. McKenzie, and A. Sharma, “Unsuspected bronchospasm in association with topical timolol—a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement?” Age and Ageing, vol. 23, no. 1, pp. 17–21, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. W. C. Stewart, D. G. Day, K. T. Holmes, and J. A. Stewart, “Effect of timolol 0.5% Gel and solution on pulmonary function in older glaucoma patients,” Journal of Glaucoma, vol. 10, no. 3, pp. 227–232, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. T. J. Zimmerman and H. E. Kaufman, “Timolol. A β-adrenergic blocking agent for the treatment of glaucoma,” Archives of Ophthalmology, vol. 95, no. 4, pp. 601–604, 1977. View at Publisher · View at Google Scholar · View at Scopus
  10. R. L. Radius, G. R. Diamond, I. P. Pollack, and M. E. Langham, “Timolol: a new drug for management of chronic simple glaucoma,” Archives of Ophthalmology, vol. 96, no. 6, pp. 1003–1008, 1978. View at Publisher · View at Google Scholar · View at Scopus
  11. M. B. Shields, Textbook of Glaucoma, Williams & Wilkins, Baltimore, Md, USA, 2nd edition, 1987.
  12. T. Nieminen, H. Uusitalo, V. Turjanmaa et al., “Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients,” European Journal of Clinical Pharmacology, vol. 61, no. 5-6, pp. 369–374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-M. Korte, T. Kaila, and K. M. Saari, “Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 240, no. 6, pp. 430–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. M. B. Affrime, D. T. Lowenthal, J. A. Tobert et al., “Dynamics and kinetics of ophthalmic timolol,” Clinical Pharmacology and Therapeutics, vol. 27, no. 4, pp. 471–477, 1980. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Alvan, B. Calissendorff, P. Seideman, K. Widmark, and G. Widmark, “Absorption of ocular timolol,” Clinical Pharmacokinetics, vol. 5, no. 1, pp. 95–100, 1980. View at Publisher · View at Google Scholar · View at Scopus
  16. W. C. Stewart and W. P. Castelli, “Systemic side effects of topical beta-adrenergic blockers,” Clinical Cardiology, vol. 19, no. 9, pp. 691–697, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Nieminen, T. Lehtimäki, J. Mäenpää, A. Ropo, H. Uusitalo, and M. Kähönen, “Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 67, no. 2, pp. 237–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. W. L. Nelson, F. T. Fraunfelder, J. M. Sills, J. B. Arrowsmith, and J. N. Kuritsky, “Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985,” The American Journal of Ophthalmology, vol. 102, no. 5, pp. 606–611, 1986. View at Google Scholar · View at Scopus
  19. D. J. Brazier and S. E. Smith, “Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers,” British Journal of Ophthalmology, vol. 72, no. 2, pp. 101–103, 1988. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Waldock, J. Snape, and C. M. Graham, “Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients,” British Journal of Ophthalmology, vol. 84, no. 7, pp. 710–713, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. W. J. Doyle, P. A. Weber, and R. H. Meeks, “Effect of topical timolol maleate on exercise performance,” Archives of Ophthalmology, vol. 102, no. 10, pp. 1517–1518, 1984. View at Publisher · View at Google Scholar · View at Scopus
  22. C. V. Leier, N. D. Baker, and P. A. Weber, “Cardiovascular effects of ophthalmic timolol,” Annals of Internal Medicine, vol. 104, no. 2, pp. 197–199, 1986. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Dickstein and T. Aarsland, “Comparison of the effect of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men,” American Journal of Ophthalmology, vol. 121, no. 4, pp. 367–371, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. M.-L. Vuori, T. Ali-Melkkila, T. Kaila, E. Iisalo, and K. M. Saari, “Plasma and aqueous humour concentrations and systemic effects of topical betaxolol and timolol in man,” Acta Ophthalmologica, vol. 71, no. 2, pp. 201–206, 1993. View at Google Scholar · View at Scopus
  25. J. Niño, K. Tahvanainen, H. Uusitalo et al., “Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel,” Clinical Physiology and Functional Imaging, vol. 22, no. 4, pp. 271–278, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Uusitalo, J. Niño, K. Tahvanainen et al., “Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel,” Acta Ophthalmologica Scandinavica, vol. 83, no. 6, pp. 723–728, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Dickstein, R. Hapnes, T. Aarsland, K. Krestianson, and L. Viksmoen, “Comparison of topical vs betaxolol on cardiopulmonary exercise performance in healthy volunteers,” Acta Ophthalmologica, vol. 66, no. 4, pp. 463–466, 1988. View at Google Scholar · View at Scopus
  28. M. H. Umetsuki, T. Kotegawa, K. Nakamura, S. Nakano, and K. Nakatsuka, “Temporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy men,” The Journal of Clinical Pharmacology, vol. 37, no. 1, pp. 58–63, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. W. C. Stewart, E. A. Cate, and J. A. Stewart, “Systemic β-blockade with once daily betimol(TM) or timoptic-XE(TM),” Journal of Ocular Pharmacology and Therapeutics, vol. 15, no. 3, pp. 225–231, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. W. C. Stewart, J. A. Stewart, S. Crockett, C. Kubilus, A. Brown, and N. Shams, “Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test,” Acta Ophthalmologica Scandinavica, vol. 80, no. 3, pp. 272–276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. W. C. Stewart, J. A. Stewart, and A. L. Jackson, “Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy,” Acta Ophthalmologica Scandinavica, vol. 80, no. 3, pp. 277–281, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Ohno, R. Takayanagi, T. Iga, Y. Yamada, M. Nagahara, and M. Araie, “Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG),” Current Eye Research, vol. 30, no. 4, pp. 319–328, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Dickstein, R. Hapnes, and T. Aarsland, “Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma,” American Journal of Ophthalmology, vol. 132, no. 5, pp. 626–632, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. Australian Government Department of Veterans' Affair, Treatment Population Statistics, 2011, http://www.dva.gov.au/aboutDVA/Statistics/Documents/TpopSep2011.pdf.
  35. World Health Organization Collaborating Centre for Drug Statistics Methodology, “ATC/DDD Index 2011,” 2011, http://www.whocc.no/atc_ddd_index/.
  36. Australian Government Department of Health and Ageing, Schedule of Pharmaceutical Benefits Canberra, National Capital Printing, 2008.
  37. National Centre for Classification in Health, The International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM), National Centre for Classification in Health, Sydney, Australia, 6th edition, 2008.
  38. H. J. Whitaker, M. N. Hocine, and C. P. Farrington, “The methodology of self-controlled case series studies,” Statistical Methods in Medical Research, vol. 18, no. 1, pp. 7–26, 2009. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  39. H. J. Whitaker, C. P. Farrington, B. Spiessens, and P. Musonda, “Tutorial in biostatistics: the self-controlled case series method,” Statistics in Medicine, vol. 25, no. 10, pp. 1768–1797, 2006. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  40. W. Y. Zhang, A. Li Wan Po, H. S. Dua, and A. Azuara-Blanco, “Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension,” The British Journal of Ophthalmology, vol. 85, no. 8, pp. 983–990, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. E. E. Roughead, L. M. Kalisch, N. L. Pratt, G. Killer, A. Barnard, and A. L. Gilbert, “Managing glaucoma in those with co-morbidity: not as easy as it seems,” Ophthalmic Epidemiology, vol. 19, no. 2, pp. 74–82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. D. Pringle and C. J. MacEwen, “Severe bradycardia due to interaction of timolol eye drops and verapamil,” British Medical Journal, vol. 294, no. 6565, pp. 155–156, 1987. View at Google Scholar · View at Scopus
  43. Australian Institute of Health and Welfare, Health Care Usage and Costs: A Comparison of Veterans and War Widows and Widowers with the Rest of the Community, Cat. no. PHE 42, AIHW, Canberra, Australia, 2002.